{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:40Z","timestamp":1761630820392},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>We report a case in which a 43-year-old African American male with medical history of sickle cell disease (SCD) presented with a nonhealing ulcer. Biopsy revealed features of livedoid vasculopathy. Previously, livedoid vasculopathy had only been described in a patient with sickle cell trait, but never in a patient with SCD. Livedoid vasculopathy most commonly affects the distal lower extremities and is characterized by irregular, punched-out, painful ulcers that heal with stellate white scars of atrophie blanche. Histologically, it reveals segmental hyalinizing vessels, focal thrombosis, and endothelial proliferation. The etiology is currently unclear, but it has been shown to be related to procoagulant states and a diagnosis of livedoid vasculopathy should prompt a thorough hypercoagulable workup, including testing for SCD in high-risk patients.<\/jats:p>","DOI":"10.1097\/dad.0000000000001133","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T16:21:22Z","timestamp":1520958082000},"page":"682-685","source":"Crossref","is-referenced-by-count":9,"title":["Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease"],"prefix":"10.1097","volume":"40","author":[{"given":"Heather","family":"Reagin","sequence":"first","affiliation":[{"name":"University of North Texas Health Science Center, Fort Worth, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etan","family":"Marks","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Weis","sequence":"additional","affiliation":[{"name":"University of North Texas Health Science Center, Fort Worth, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Susa","sequence":"additional","affiliation":[{"name":"Division of Dermatopathology, Cockerell Dermatopathology, Dallas, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.autrev.2010.11.008","article-title":"Livedoid vasculopathy as a coagulation disorder","volume":"10","author":"Criado","year":"2011","journal-title":"Autoimmun Rev."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2015.08.071","article-title":"Coagulation disorders and their cutaneous presentations: diagnostic work-up and treatment","volume":"74","author":"Dabiri","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2133.1999.02622.x","article-title":"Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?","volume":"140","author":"Acland","year":"1999","journal-title":"Br J Dermatol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","article-title":"Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach","volume":"69","author":"Alavi","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1742-481X.2011.00882.x","article-title":"Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment","volume":"9","author":"El Khoury","year":"2012","journal-title":"Int Wound J."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mjd.2002.117718","article-title":"Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation","volume":"46","author":"Calamia","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2007.06740.x","article-title":"Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability","volume":"139","author":"Ataga","year":"2007","journal-title":"Br J Haematol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00277-015-2531-8","article-title":"Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK","volume":"95","author":"van Hamel Parsons","year":"2016","journal-title":"Ann Hematol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1534734615600069","article-title":"Hemoglobinopathies and leg ulcers","volume":"14","author":"Alavi","year":"2015","journal-title":"Int J Low Extrem Wound."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","article-title":"Hydroxyurea-induced leg ulceration in 14 patients","volume":"128","author":"Best","year":"1998","journal-title":"Ann Intern Med."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.24134","article-title":"Critical Reviews: how we treat sickle cell patients with leg ulcers","volume":"91","author":"Minniti","year":"2016","journal-title":"Am J Hematol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2006.04.087","article-title":"Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin","volume":"58","author":"Davis","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"R14-20230908","first-page":"407","article-title":"Livedoid vasculopathy\u2014current aspects of diagnosis and treatment of cutaneous infarction","volume":"11","author":"Kerk","year":"2013","journal-title":"J Dtsch Dermatol Ges."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)60922-7","article-title":"Tissue plasminogen activator for treatment of livedoid vasculitis","volume":"67","author":"Klein","year":"1992","journal-title":"Mayo Clinic Proc."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/archderm.1988.01670050028013","article-title":"Livedo vasculitis. Therapy with pentoxifylline","volume":"124","author":"Sams","year":"1988","journal-title":"Arch Dermatol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.142.1.75","article-title":"Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia","volume":"142","author":"Browning","year":"2006","journal-title":"Arch Dermatol."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11239-012-0743-5","article-title":"Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin","volume":"34","author":"Abou Rahal","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.139.8.987","article-title":"Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases","volume":"139","author":"Hairston","year":"2003","journal-title":"Arch Dermatol."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjd.12100","article-title":"Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy","volume":"168","author":"Kerk","year":"2013","journal-title":"Br J Dermatol."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/JPR.S133462","article-title":"Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy","volume":"10","author":"Chen","year":"2017","journal-title":"J pain Res."},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-4362.1990.tb04768.x","article-title":"Treatment of sickle cell leg ulcers with pentoxifylline","volume":"29","author":"Frost","year":"1990","journal-title":"Int J Dermatol."},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000322248","article-title":"Clinical follow-up of hydroxyurea-treated adults with sickle cell disease","volume":"125","author":"Nzouakou","year":"2011","journal-title":"Acta haematologica."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann Intern Med."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201809000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:07:50Z","timestamp":1694149670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201809000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001133","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}